FCCC LOGO Faculty Publications
Martenson JA , Lipsitz SR , Lefkopoulou M , Engstrom PF , Dayal YY , Cobau CD , Oken MM , Haller DG
Results of Combined-Modality Therapy for Patients with Anal Cancer (E7283) - an Eastern-Cooperative-Oncology-Group-Study
Cancer. 1995 Nov 15;76(10) :1731-1736
PMID: ISI:A1995TC71800008   
Back to previous list
Background. This prospective study assessed combined modality therapy of patients with International Union Against Cancer classification T1-4 NO MO anal cancer. Methods. Protocol therapy consisted of a dose of 4000 cGy to the pelvis, anus, and perineum, followed by a 1000-1300 cGy boost. Infusions of 5-fluorouracil and mitomycin-C were administered when radiation therapy began. A second infusion of 5-fluorouracil was administered 28 days later. Biopsy was performed 6-8 weeks after completion of treatment. Positive biopsy findings resulted in abdominal-perineal resection. Results. Survival at 7 years for 50 eligible patients was 58%. White patients and those with favorable performance status had significantly better survival. Of the 46 patients evaluable for response, 34 had a complete response, 11 had a partial response, and 1 had no response. Seven-year survival for partial responders was 53%. Freedom from locoregional progression was 80% at 7 years. Conclusion. Treatment with a combination of chemotherapy and radiation therapy is effective for patients with anal cancer. The investigation of methods of improving therapy is warranted.
Times Cited: 10 Article TC718 CANCER